ASH 2020 | TG-1701: a BTK inhibitor for B-cell malignancies
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses the Phase I trial (NCT03671590) assessing the safety and efficacy of the Burton’s tyrosine kinase (BTK) inhibitor TG-1701 in patients with relapsed/refractory (R/R) B-cell malignancies, including chronic lymphocytic leukemia (CLL). TG-1701 was evaluated as a monotherapy, or in combination with ublituximab and umbralisib (U2). The trial included a dose-escalation cohort and a dose-expansion cohort of specific B-cell malignancies, including CLL, Waldernström’s macroglobulinemia (WM), and mantle cell lymphoma (MCL). The combination of TG-1701 plus U2 showed promising clinical activity and enhanced depth of response over TG-1701 monotherapy with no additional toxicity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
